These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35984342)

  • 1. Predictive values of PD‑L1 expression for survival outcomes in patients with cervical cancer: a systematic review and meta-analysis.
    Hu T; Wan X; Wu H; Cheng X; Xu S
    Ginekol Pol; 2022; 93(10):767-774. PubMed ID: 35984342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
    Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
    Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.
    Xian F; Ren D; Bie J; Xu G
    Front Immunol; 2023; 14():1119168. PubMed ID: 37138876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
    Zhang C; Yang Q
    Front Oncol; 2020; 10():572203. PubMed ID: 33634012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
    Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
    JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
    Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
    Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis.
    Fitzsimmons TS; Singh N; Walker TDJ; Newton C; Evans DGR; Crosbie EJ; Ryan NAJ
    Front Med (Lausanne); 2023; 10():1192762. PubMed ID: 37250628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis.
    Wang C; Zhu H; Zhou Y; Mao F; Lin Y; Pan B; Zhang X; Xu Q; Huang X; Sun Q
    Breast J; 2017 Jul; 23(4):436-443. PubMed ID: 28079291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CD274 (PD-L1) overexpression on survival outcomes in 10 specific cancers: a systematic review and meta-analysis.
    Park JH; Luchini C; Nottegar A; Tizaoui K; Koyanagi A; Ogino S; Shin JI; Lim BJ; Smith L
    J Clin Pathol; 2023 Jul; 76(7):450-456. PubMed ID: 37130750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.
    Wang Q; Liu F; Liu L
    Medicine (Baltimore); 2017 May; 96(18):e6369. PubMed ID: 28471952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of anti-PD-1/PD-L1 in treatment of glioma: a single-arm meta-analysis.
    Zeng YF; Wei XY; Guo QH; Chen SY; Deng S; Liu ZZ; Gong ZC; Zeng WJ
    Front Immunol; 2023; 14():1168244. PubMed ID: 37122727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis.
    Li J; Wang P; Xu Y
    PLoS One; 2017; 12(6):e0179536. PubMed ID: 28604812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Acheampong E; Abed A; Morici M; Bowyer S; Amanuel B; Lin W; Millward M; Gray ES
    Cells; 2020 Oct; 9(11):. PubMed ID: 33142852
    [No Abstract]   [Full Text] [Related]  

  • 16. Programmed Cell Death Ligand 1 Expression on Immune Cells and Survival in Patients With Nonmetastatic Head and Neck Cancer: A Systematic Review and Meta-analysis.
    Blažek T; Petráš M; Knybel L; Cvek J; Soumarová R
    JAMA Netw Open; 2023 Mar; 6(3):e236324. PubMed ID: 37000447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological and prognostic values of PD-L1 expression in oesophageal squamous cell carcinoma: a meta-analysis of 31 studies with 5368 patients.
    Liu Z; Sun L; Cai L; Guo M; Xu G; Liu S; Zheng G; Wang Q; Lian X; Feng F; Zhang H
    Postgrad Med J; 2022 Dec; 98(1166):948-957. PubMed ID: 34253568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.
    Wang Z; Peng S; Xie H; Guo L; Cai Q; Shang Z; Jiang N; Niu Y
    Clin Exp Med; 2018 May; 18(2):165-175. PubMed ID: 29362922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of PD-L1 expression in pancreatic cancer: evidence from an updated meta-analysis.
    Liu C; Fan L; Wu Q; Shi Y; Sun X
    Pol J Pathol; 2023; 74(3):151-160. PubMed ID: 37955534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis.
    Cheng Y; Wang C; Wang Y; Dai L
    Future Oncol; 2022 Jan; 18(2):261-273. PubMed ID: 34874185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.